Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 01643 MODERN CHI MED > Detailed Quotes

01643 MODERN CHI MED

Watchlist
0.475
+0.005+1.06%
Market Close 12/02 16:08 CCT
High
0.475
Open
0.475
Turnover
72.68K
Low
0.475
Pre Close
0.470
Volume
153.00K
Market Cap
285.00M
P/E(TTM)
2.70
52wk High
1.053
Shares
600.00M
P/E(Static)
2.84
52wk Low
0.400
Float Cap
285.00M
Bid/Ask %
-65.64%
Historical High
1.383
Shs Float
600.00M
Volume Ratio
1.00
Historical Low
0.400
Dividend TTM
0.017
Div Yield TTM
0.017
P/B
0.64
Dividend LFY
3.58%
Div Yield LFY
3.58%
Turnover Ratio
0.03%
Amplitude
0.00%
Avg Price
0.475
Lot Size
3000
Float Cap
285.00M
Bid/Ask %
-65.64%
Historical High
1.383
Shs Float
600.00M
Volume Ratio
1.00
Historical Low
0.400
Dividend TTM
0.017
P/B
0.64
Dividend LFY
3.58%
Turnover Ratio
0.03%
Amplitude
0.00%
Avg Price
0.475
Lot Size
3000
Price Forecast

No Data

News

Comment

No Data

Company Overview More
Modern traditional Chinese Medicine Group Co., Ltd. is one of the forerunners of the modernization of traditional Chinese medicine. Chengde Yushi Jindan Pharmaceutical Co., Ltd. is a proprietary Chinese medicine pharmaceutical enterprise with a long history. Our development history can be traced back to 1986, adhering to the corporate mission of "building a national traditional Chinese medicine industry and focusing on the healthy development of national traditional Chinese medicine". Has been focused on the innovative development of invigorating qi and blood, cardio-cerebrovascular, digestive system, gynecological proprietary Chinese medicine, novel coronavirus and / or similar diseases (since fiscal year 1986). We have 71 drug approval numbers and produce 59 kinds of proprietary Chinese medicine products, of which 45 are listed in the National Medical Insurance Drug catalogue. It is a leading manufacturer of proprietary Chinese medicine pills and cardio-cerebrovascular proprietary Chinese medicine capsules in Northeast China. We have main product groups such as Qixue Shuangbu pills, Bushen Bujing pills, Shanmei capsules, Jinkui Shenqi pills, Xinan capsules, Jiawei Xiaoyao pills, Jiawei Huoxiang Zhengqi pills, Qingwen jiedu pills and liver protection tablets. Among them, Bushen Fengjing pills, Qixue Shuangbu pills and Shanmei capsule occupy a leading position in the market. We have implemented a strict quality control system, established a sound enterprise management system and various operating rules, built a first-class elite team of management, production and distribution, and realized the standardized management of the enterprise. We promote enterprise development through research and development, and enter into cooperation agreements with Heilongjiang University of traditional Chinese Medicine and Chengde Medical College to jointly carry out research and development of new drugs and strengthen our product expertise. Shanmei capsule, the main product of the company, is the original research medicine, which was issued by the Ministry of Health of China in 1995 and was listed as a second-class protected variety of traditional Chinese medicine by the China Drug Administration. In 2016, it was awarded the reputation of famous brand products for small and medium-sized enterprises in Hebei Province by the Department of Industry and Information Technology of Hebei Province. Relying on geography and our own advantages, we are based in Hebei, while ploughing the markets in North and Northeast China, we vigorously expand the markets in East China, South China, Southwest and Northwest, and gradually build up an efficient marketing network covering the whole country. After years of development, we have established a unique brand advantage. "Royal Room" brand products are trusted by our customers because of their competitiveness and diversified combinations, and enjoy a high reputation in the national pharmaceutical market. Entering the 21st century, enterprises have formulated the development direction of "collectivization, intensification and internationalization", with the aim of building a domestic first-class and internationally well-known modern large-scale traditional Chinese medicine pharmaceutical group.
CEO: Wei Xie
Market: Hong Kong motherboard
Listing Date: 01/15/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist